Fulgent Genetics Acquires Inform Diagnostics from Avista Capital Partners

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Versant Diagnostics Acquires Two Chicago-Area Pathology Practices

July 11, 2022

Healthcare Services

Versant Diagnostics, a PE-backed independent physician services company, acquired Pathology Consultants of Chicago and the operating assets of Elgin Laboratory Physicians to expand its footprint in the greater-Chicago market. The deals (Versant's third and fourth acquisitions in nine months) support the company's strategy to consolidate pathology practices and accelerate digital pathology conversion with growth capital backing from Iron Path Capital and financing support from Principal.

LabGenomics USA LLC Acquires QDx Pathology

September 5, 2023

Healthcare Services

LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

EmeritusDX Acquires Freedom Pathology Partners

June 13, 2022

Healthcare Services

EmeritusDX, a cancer diagnostics and information company, has acquired Freedom Pathology Partners, a CAP- and CLIA-accredited laboratory based in Conshohocken, Pennsylvania. The acquisition expands EmeritusDX’s national presence and test menu—adding anatomic pathology, FISH, and molecular testing capabilities and strengthening relationships in dermatology, gastroenterology, and urology markets.

FUJIFILM Acquires Inspirata's Digital Pathology Business

December 19, 2022

Healthcare Services

FUJIFILM Corporation entered into an asset purchase agreement to acquire the global digital pathology business of Tampa-based Inspirata, Inc., including the Dynamyx technology, associated employees and customers. The acquisition expands FUJIFILM's Synapse Enterprise Imaging portfolio to add digital pathology capabilities and support integration of pathology images and data across healthcare organizations.